CAS RN: 1109276-89-2

PF-04620110

Product Availability

Choose a grade to view its available package options.

7 package records5 with current stock1 grade group
Batch No.PackageAvailabilityWarehouseInquiry
Batchno.20250803 100mg In stock Shanghai Inquiry
Batchno.20250606 10mg Out of stock Inquiry
Batchno.20251209 250mg Out of stock Inquiry
Batchno.20260114 25mg In stock Shanghai Inquiry
Batchno.20250528 50mg In stock Shanghai Inquiry
Batchno.20251114 5mg In stock Shanghai Inquiry
Batchno.20250716 5mg / 25mg Confirm by inquiry Shanghai Inquiry
  • Product code: starshine_CAS1109276-89-2
  • Purity/Analytical Methods: >99.0%
GET A QUOTE

1109276-89-2 / 2-[4-[4-(4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6-yl)phenyl]cyclohexyl]acetic acid

PF-04620110 | PF 04620110 | PF-4620110

Standard CAS: 1109276-89-2 Multi CAS: Yes

Basic Information

CAS
1109276-89-2
Multi CAS
Yes
Molecular Formula
C21H24N4O4
Molecular Weight
396.400000
Exact Mass
396.179755
SMILES
C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)N3CCOC4=NC=NC(=C4C3=O)N
InChI
InChI=1S/C21H24N4O4/c22-19-18-20(24-12-23-19)29-10-9-25(21(18)28)16-7-5-15(6-8-16)14-3-1-13(2-4-14)11-17(26)27/h5-8,12-14H,1-4,9-11H2,(H,26,27)(H2,22,23,24)
InChIKey
GEVVQZHMFVFGLN-UHFFFAOYSA-N
Synonyms
PF-04620110 PF 04620110 PF-4620110 CQ4M18RLJW CHEMBL1835919

Computed Properties

Structural Parameters

Heavy atom count
29
Aromatic heavy atom count
12
Fraction Csp3
0.43
Rotatable bonds
4
H-bond acceptors
6
H-bond donors
2
Molar refractivity
107.01
TPSA
118.64

LogP / Solubility

WLOGP
2.85
MLOGP
2.53
XLogP3
3.3
Consensus LogP
2.89
Log S (ESOL)
-4.13
Class (ESOL)
Slightly soluble
Log S (Ali)
-4.87
Class (Ali)
Slightly soluble
Log S (SILICOS-IT)
-5.08
Class (SILICOS-IT)
Slightly soluble

ADME

GI absorption
High
BBB permeant
No
P-gp substrate
No
CYP1A2 inhibitor
Yes
CYP2C19 inhibitor
Yes
CYP2C9 inhibitor
No
CYP2D6 inhibitor
Yes
CYP3A4 inhibitor
Yes
Log Kp (skin permeation)
-3.12

Drug-likeness / Medicinal Chemistry

Lipinski
Yes
Ghose
Yes
Veber
Yes
Egan
Yes
Muegge
Yes
Bioavailability score
0.55
Leadlikeness
No
Synthetic Accessibility
3

Get In Touch

Contact Us